The pharmacokinetics of ofloxacin were studied in 12 intensive care patients, 6 of whom were under controlled mechanical ventilation. All patients had a creatinine clearance of >80 ml/min per 1.73 M2. They were given 3 mg of ofloxacin per kg of body weight intravenously at a constant flow rate in 30 min twice a day for 7 days. Pharmacokinetic studies were performed on days 1 and 7. Between days 1 and 7, significant increases in the alpha (distribution) and beta (elimination) phase half-lives, the area under the serum concentration-time curve, and peak and trough levels in serum were observed, together with a marked decrease (>50%) in total body clearance. Possible contributing factors for alteration of oflaxacin pharmacokinetics in ventilated patients were patient age, liver dysfunction, drug interaction, and drug accumulation in a deep compartment. This study shows that in intensive care patients the pharmacokinetics of ofloxacin differ from those reported for healthy volunteers.
Critically ill patients with acute pathologic changes have numerous disorders induced by the causal disease and/or concurrent therapy. These subjects usually receive multiple associated treatments whose cumulative effects are not always predictable, especially in terms of drug elimination. As for antibiotics, it has been demonstrated that various pharmacokinetic disorders can occur in intensive care patients during administration of aminoglycosides (1, 12) , beta-lactams (1), or a quinolone (11) .
Compared with the results obtained with healthy volunteers, these modifications can lead to changes in the method of administration, i.e., dosage and frequency of injections (1, 12) . The aim of this study was to evaluate possible modifications in ofloxacin pharmacokinetics administered to intensive care patients compared with normal subjects.
MATERIALS AND METHODS
This open and prospective study included two groups of patients admitted consecutively to an intensive care unit. The first group consisted of six patients without respiratory problems and therefore without mechanical ventilation. The second group included six patients who were on mechanical ventilation for a minimum of 7 days. These six patients remained under controlled ventilation during the whole study. All of the patients had nosocomial infections with organisms susceptible to ofloxacin. They all had a creatinine clearance of >80 m/min per 1.73 M2. Urine was collected over a 24-h period by an indwelling urinary catheter. Urine and serum creatinine was determined by the Jaffd method by using picric acid in alkaline medium. Creatinine clearance was calculated with the formula (U x V)/P (10), where U is urine creatinine, V is 24-h urine, and P is serum creatinine. Ofloxacin was given intravenously at a dose of 3 mg/kg, twice daily, for a minimum of 7 to infinity (AUC OO), total plasma clearance (CL), and central volume of distribution (V). All of these parameters were calculated by using standard formulas (16) . Because of the blood sampling schedule, elimination (beta phase) half-life estimation was difficult on day 7 (marked increase in ofloxacin trough levels in serum). Thus, comparisons of AUC between days 1 and 7 were performed by using AUCO_12 instead of AUC<,_ and calculations of CL and V on day 7
were also performed by using AUCO_12 On day 1, CL and V were calculated by using AUC,OO. Table 1 . In the nonventilated group, the underlying diseases were multiple trauma (one patient), gastrectomy for cancer (one patient), occlusion (one patient), and AIDS (one patient). Associated diseases in the ventilated group were acute-phase myocardial infarction (one patient), multitrauma (one patient), and colectomy for cancer (one patient). There were no differences between the two groups at the beginning of the study (day 1) with respect to the parameters presented in Table 2 , except for the level of bilirubin. In addition, there were no differences between the two groups in the following parameters: prothrombin time, protidemia, alkaline phosphatase, and serum transaminase. Table 3 presents the evolution of the pharmacokinetic parameters. At the time of inclusion, the two groups did not differ in tl/2., t1/213 AUCG 12, CL, or V. On day 7, there was a significant increase in t4/2,9 tj/2., and AUCO12 in both groups. AR of these modifications were greater in the ventilated group. Since CL and V were calculated by using AUC,OO on day 1 and AUCO_12 on day 7, no statistical evaluation was performed on these parameters but a marked decrease (>50%) in CL was observed in the group of ventilated patients. No modification in biological parameters was noted, except for a significant bilirubin level increase in the ventilated group. Figures 1 and  2 present the evolution of ofloxacin levels in serum in both groups. In the ventilated group, peak levels in serum (1 min) increased from 12.6 ± 3.1 mg/liter on day 1 to 20 ± 6 mg/liter on day 7 (P < 0.01) and trough levels (12 h) increased from 1.4 ± 0.05 mg/liter on day 1 to 6.4 ± 4 mg/liter on day 7 (P < 0.02). In the nonventilated group, only trough levels were significantly increased, from 1.1 ± 0.4 mg/liter on day 1 to 3.4 ± 1.5 mg/liter on day 7 (P < 0.05).
DISCUSSION
Pharmacokinetic studies of ofloxacin in healthy subjects after both oral and parenteral administrations have been well documented (2-5, 7-9, 14, 15). The characteristics determined after a single dose are excellent bioavailability (close to 1), a tl/2,3 of 5 to 7 h, an elevated V (approximately 2 liters/kg), very low metabolism (less than 5% of the dose), rapid elimination almost exclusively through the kidneys in unchanged form, and low binding to plasma proteins (approximately 10%).
During repeated administration of ofloxacin, a low level of drug accumulation (near 1.5) has been noted in some studies (3, 4, 7) but not in others (5, 8) . However, these studies were performed for short periods (3 or 4 days) and with healthy volunteers (4, 5, 7, 8) . There is no available information on the possible pharmacokinetic modifications of ofloxacin in patients with unstable situations or major modifications in physiological functions. The present study on this type of patient, with a particular interest in subjects on mechanical ventilation, revealed differences from the results obtained with healthy volunteers. On administration of ofloxacin on day 1, there were no differences between the two groups and their pharmacokinetic parameters differed little from those previously reported, except perhaps in slightly lower values for CL and V and slightly higher-than-normal values for AUC (3-8, 13, 14) . This can probably be explained by the fact that the present study was performed with relatively old patients (15 rule out a type II error because of the small sizes of our two groups. Thus, we may have missed a significant difference in this parameter. Part of our results may be explained by the fact that age is a factor known to alter the parmacokinetics of ofloxacin (15) . However, the phenomenon of drug accumulation was also seen in the group of patients with a lower mean age (nonventilated patients). The role of concurrent therapeutics, given in association with ofloxacin, can also be discussed. More patients in the ventilated group were receiving concomitant therapy (Table 1) , probably because of more severe underlying conditions, but none of the drugs used are known to interfere with ofloxacin elimination. The use of magnesium-aluminum hydroxide (Maalox) in each patient deserves special attention, since it would prevent any enterohepatic recycling of ofloxacin because of chelate formation. Although the main route of ofloxacin elimination is through the kidneys in unchanged form, part of the drug is eliminated by nonrenal clearance. The ventilated patients exhibited some biological signs of liver dysfunction (especially a marked increase in bilirubin level). This impairment of liver function could partly explain the perturbation in ofloxacin pharmacokinetics. Quinolones are antibiotics that can be ion-trapped inside cells. Thus, accumulation in a deep tissue compartment may occur after multiple dosing. The present study was carried out under real-life conditions, and only nine sampling times were scheduled; thus, tricompartmental analysis could obviously not be performed. By using a simpler two-compartment model, we may have missed demonstration of the existence of a deep-tissue compartment. The decrease in OFLOXACIN (mg/1) 20 CL, as this deep site becomes saturated, may also be explained by the use of a simpler, "incorrect" model.
As renal elimination accounts for most ofloxacin clearance, renal impairment has a major impact on drug disposition (6) . In the present study, evaluation of renal function was performed by calculating creatinine clearance. After collection of urine over a 24-h period and measurement of serum and urine creatinine, clearance was calculated by the standard formula (10) . The use of formulas or nomograms based on anthropometric parameters and serum creatinine measurement may lead to erroneous estimation of glomerular filtration in intensive care patients (10) . Between days 1 and 7, no significant changes in creatinine clearance were observed in the two groups. However, a risk of type II error in the statistical evaluation cannot be ruled out, since small groups of patients were studied. Thus, mild impairment of renal function in the study patients may have been missed. This could also partly explain the phenomenon of ofloxacin accumulation.
Ofloxacin levels in serum increased from days 1 to 7 as a direct consequence of drug accumulation. Since ofloxacin has excellent tolerance, this phenomenon may present a beneficial microbiological aspect in that better efficacy can be achieved against certain organisms for which the MIC is high. If, however, one wishes to maintain serum levels within normal ranges, a reduction in the dose or an increase in the time between injections, beginning on 4 or 5, should probably be considered.
In conclusion, this study shows that in intensive care patients with clinical instability and mechanical ventilation, OFLOXACIN 
